Radiant Biotherapeutics’ Multabodies are antibodies engineered to offer better binding strength to their targets. The preclinical startup’s lead program goes after a cancer immunotherapy target being pursued by several biotech companies already in early clinical development.
Emergent BioSolutions’ smallpox vaccine, ACAM2000, now has an additional FDA approval covering mpox. It’s one of two FDA-approved mpox vaccines, joining Jynneos from Bavarian Nordic.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
GSK is taking over development of an avian influenza vaccine candidate as a bird flu outbreak continues in U.S. dairy cows. Meanwhile, CureVac is restructuring and returning its attention to cancer vaccines, which was the initial focus of the mRNA company.
Bavarian Nordic will concentrate on its portfolio and pipeline of infectious diseases vaccines, including top seller Jynneos, approved for mpox and smallpox. The company only had one clinical-stage cancer vaccine program.
Marburg virus has no FDA-approved vaccines or therapies, but a vaccine candidate from the National Institutes of Health now has encouraging results from a U.S. clinical trial. Next steps include tests in more countries including Ghana, where a Marburg outbreak was declared last summer.
Respiratory syncytial virus has no approved vaccines anywhere in the world, but the chase to bring the first one to the market is heating up. GSK reported Phase 3 data that position it for regulatory submissions the pharma giant is planning for later this year. Pfizer is also on track to seek regulatory approvals for its RSV vaccine candidate.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Shares of the company were up more than 13 percent on the Tel Aviv Stock Exchange following the approval of Talicia, meant to address the growing issue of the bacteria's resistance to antibiotics. H. pylori is a major cause of gastric cancer.
Harvard’s Wyss Institute and VC firm Miraki Innovation have created a joint venture BOA Biomedical, which is developing a device that could diagnose and treat infectious diseases.
The company, which is called Infectious Disease (ID) Connect, aims to virtually connect UPMC infectious disease specialists to other hospitals.
The study, conducted with St. Jude Children's Research Hospital, showed a 78 percent predictive sensitivity two days before the onset of infection.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
The ultimate goal of MeMed is to right-size antibiotic use. The team is working on a second-generation platform that gets results in minutes and that anyone can use.
Many infectious diseases could now be tackled by Sherwin Williams' new paint designed to kill certain bacteria for up to four years.
It's possible that the air we are breathing could be identifying, much like a fingerprint or DNA from our hair.
Another deadly infection blights the US yet again, this time in California. We all saw the news of the outbreak of carbapenem-resistant Enterobacteriaceae (CRE) at UCLA’s Ronald Reagan Medical Center. The origin stemmed from duodenoscopes used at that hospital. This closely follows on the heels of the measles ( a virus previously considered eradicated from […]
Ebola is taking over the news, but is it the disease we should really be worried about? According to Toby Cosgrove, CEO and President at Cleveland Clinic, as many as 3,000 to 49,000 Americans could die from the flu in the next four to six months. As Cosgrove says: Over the past 30 years, the Centers […]